Will the Phase 3 trial "A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus" reach primary completion on or before Dec 6, 2028?

Resolves Yes if ClinicalTrials.gov record NCT07438496 (Janssen Research & Development, LLC) shows an actual primary completion date on or before Dec 6, 2028. Registered date at generation: Dec 6, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Dec 6, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.